Hanauer, S B <br/><br/>
Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial.  [electronic resource] 

 -  Canadian journal of gastroenterology = Journal canadien de gastroenterologie  Dec 2007 
 - 827-34 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0835-7900 
<br/><br/><label>Standard No.: </label>10.1155/2007/862917  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Adolescent<br/>Adult<br/>Aged<br/>Anti-Inflammatory Agents, Non-Steroidal--administration & dosage<br/>Colitis, Ulcerative--diagnosis<br/>Delayed-Action Preparations<br/>Dose-Response Relationship, Drug<br/>Double-Blind Method<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Male<br/>Mesalamine--administration & dosage<br/>Middle Aged<br/>Retrospective Studies<br/>Severity of Illness Index<br/>Sigmoidoscopy<br/>Treatment Outcome